Dual PPARα/γAgonism Normalizes Lipoprotein Profile of Renal Dyslipidemia

Apolipoprotein CIII Links Dyslipidemia with Atherosclerosis

(2011) Akio Kawakami et al.   Journal of Atherosclerosis and Thrombosis

Persistent Inflammation as a Catalyst for Other Risk Factors in Chronic Kidney Disease: A Hypothesis Proposal

(2009) J. J. Carrero et al.   Clinical Journal of the American Society of Nephrology

Dyslipidemia of kidney disease

(2009) Per-Ola Attman et al.   CURRENT OPINION IN LIPIDOLOGY

Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function – evidence of interconversion

(2008) Bengt Hamrén et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment

(2008) John J.P. Kastelein et al.   CIRCULATION

Increased Plasma Apolipoprotein C-III Concentration Independently Predicts Cardiovascular Mortality: The Hoorn Study

(2008) P. G. Scheffer et al.   CLINICAL CHEMISTRY

An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?

(2008) D. C. Chan et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Lipid Abnormalities and Cardiovascular Risk in Renal Disease

(2008) E. Ritz et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies

(2008) Theodore Mazzone et al.   LANCET

Tesaglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance

(2007) Herbert Schuster et al.   ATHEROSCLEROSIS

Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney Disease

(2007) C. A. Schneider et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY